$heff's $tation of $tocks & $olid DD

[AtlasSnuggled]

RGDX management - common ancestry with CBMX

sorry for the hodge podge, was distilling info from Co website,
but CEO has a great CV. Solid surrounding players too.

Thomas A. Bologna CEO 12/11 to current.
prior experience;
P, CEO Orchid Cellmark, Inc. 4/06 - 12/11
"Dec 16, 2011 - LabCorp secures >90% of Orchid Cellmark shares, clearing a speedy close to the $85 million short-form merger acquisition…after waiting eight months for US FTC blessings. Orchid traded from 1.39 to 1.99 in the year before the offer/acquisition for ~2.80/share.

P CEO BOD of venture-backed Quorex Pharmaceuticals, Inc., where he orchestrated a successful sale to Pfizer Inc.

COB, P, CEO of Ostex International, oversaw the sale of Ostex to Alere Inc. (formally Inverness Medical Innovations).

P, CEO of Scriptgen Pharmaceuticals, Inc
COB, P, CEO Gen-Probe, Inc (global leader in the development, manufacture and marketing of molecular diagnostic products), leading Gen-Probe through IPO on NASDAQ to sale to Chugai Pharma.

Mr. Bologna held senior-level positions with Becton Dickinson & Company and Warner-Lambert Company (Pfizer)
Mr. Bologna served as President of the Becton Dickinson Diagnostic Instrument Systems Division and as a Vice President of the Warner-Lambert Company.

Stephanie H. Astrow, PhD, VP R&D
Scientific Director for Oncology at Quest Diagnostics
Vice President and Director of Oncology at Pathway Diagnostics, and Vice President, Scientific Director of Impath, Inc.

Mark Balsano: VP Sales 4/13- present
Prior
VP Sales at Poplar Healthcare, leading the Oncology and Women’s Healthcare Divisions.
VP Sales and Marketing at Consultants in Radiology.

Alan Cheeks, M.A.: Sr Dir Laboratory Operations July, 2012,
13 years of laboratory and operations management experience i
Prior
Peregrine Pharmaceuticals, managed clinical trial operations for the oncology pipeline.
Quest Diagnostics managed the clinical studies team
IMPATH Dir Clinical Trials at Pathway Diagnostics
Director of Cellular Oncology at IMPATH.

other
http://www.responsegenetics.com/about-us/management-and-board/

BOD
Kirk K. Calhoun Ernst & Young LLP1965 (1975 partner) 2002 ret.
Served on BOD and Audit of 5 pharma Cos … up to their respective sales (Abraxis Biosci, Myogen, Aspreva Pharma., Replidyne, Adams Respiratory Therapeutics,)

Sam Chawla
Portfolio Manager of Perceptive Advisors LLC, Credit Opportunities Fund
Managing Director at UBS Securities
Director, VP in the Healthcare Investment Banking Group of Credit Suisse LLC
David R. Schreiber
25 years executive in diagnostics.

more

note, long RGDX